MADE POSSIBLE BY:
MADE POSSIBLE BY:
Home Tags Hodgkin lymphoma

Tag: Hodgkin lymphoma

First Patient Dosed in Phase Ib Clinical Trial of Camidanlumab Tesirine...

A first patient has been dosed in Phase Ib clinical trial of camidanlumab tesirine, also know ADCT-301, a proprietary antibody-drug conjugate or ADC being...

ASH 2018 Highlights Progress in Ongoing Development of Brentuximab Vedotin

As the premier hematology event in malignant and non-malignant hematology, the annual meeting of the American Society of Hematology (ASH), held this year from...

Interim Results from Ongoing Studies of Brentuximab Vedotin + Nivolumab in...

Multiple presentations evaluating brentuximab vedotin (Adcetris®; Seattle Genetics/Takeda*) across a broad range of Hodgkin lymphoma (HL) settings were presented at the 11th International Symposium...

Brentuximab Vedotin in Combination with Chemotherapy Approved for Adults with Previously...

The U.S. Food and Drug Administration (FDA) has approved brentuximab vedotin (Adcetris®; Seattle Genetics/Takeda) in combination with chemotherapy in adult patients with previously untreated...

U.S. FDA Grants Priority Review for Brentuximab Vedotin in Frontline Advanced...

Based on positive results from the Phase III ECHELON-1 clinical trial, the U.S. Food and Drug Administration (FDA) has accepted for filing a supplemental...

Interim Phase I Data from Camidanlumab Tesirine (ADCT-301) Shows Encouraging Preliminary...

Clinical data from two ongoing Phase I clinical trials evaluating camidanlumab tesirine, also known as ADCT-301* or "Cami-T", in important subtypes of lymphoma and...

Supplemental Biologics License Application for Brentuximab Vedotin in Frontline Advanced Hodgkin...

Based on positive results from the Phase III ECHELON-1 Clinical Trial evaluating brentuximab vedotin (Adcetris®; Seattle Genetics) in combination with chemotherapy for the frontline...

Positive Results from Phase III ECHELON-1 Trial Evaluating Brentuximab Vedotin in...

ECHELON-1, a randomized, multicenter, phase III clinical trial evaluating brentiximab vedotin (Adcetris®) as part of a combination chemotherapy regimen in 1,334 patients with advanced...

Updates from the 14th International Conference on Malignant Lymphoma (ICML)

Since the inaugurational meeting in 1981, the International Conference on Malignant Lymphoma (ICML), traditionally takes place in Lugano, Switzerland, has become one of the...

Combination of Brentuximab Vedotin and Nivolumab Shows 85% Objective Response Rate...

An updated interim analysis from the ongoing phase I/II clinical trial evaluating  brentuximab vedotin (Adcetris®; Seattle Gentics) and nivolumab (Opdivo®; Bristol-Myers Squibb) in relapsed...